{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:14:53Z","timestamp":1792055693280,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2005,12,1]]},"DOI":"10.1038\/ncponc0347","type":"journal-article","created":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T10:09:15Z","timestamp":1134382155000},"page":"S12-S23","source":"Crossref","is-referenced-by-count":62,"title":["Methylation inhibitor therapy in the treatment of myelodysplastic syndrome"],"prefix":"10.1038","volume":"2","author":[{"given":"Lewis R","family":"Silverman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam J","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"Suppl 6","key":"BFncponc0347_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/10732748040110S602","volume":"11","author":"S Gore","year":"2004","unstructured":"Gore S (2004) Classification, treatment goals, and management principles for myelodysplastic syndromes. Cancer Control 11 (Suppl 6): 3\u20136","journal-title":"Cancer Control"},{"key":"BFncponc0347_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM et al. (1976) Proposals for the classification of the acute leukaemias: French\u2013American\u2013British (FAB) cooperative group. Br J Haematol 33: 451\u2013458","journal-title":"Br J Haematol"},{"key":"BFncponc0347_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM et al. (1982) Proposals for the classifications of myelodysplastic syndromes. Br J Haematol 51: 189\u2013199","journal-title":"Br J Haematol"},{"key":"BFncponc0347_CR4","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM et al. (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 103: 620\u2013625","journal-title":"Ann Intern Med"},{"key":"BFncponc0347_CR5","first-page":"131","volume":"72","author":"JM Bennett","year":"2000","unstructured":"Bennett JM (2000) World Health Organization classficiation of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72: 131\u2013133","journal-title":"Int J Hematol"},{"key":"BFncponc0347_CR6","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"Greenberg","year":"1997","unstructured":"Greenberg et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndrome. Blood 89: 2079\u20132088","journal-title":"Blood"},{"issue":"Suppl 6","key":"BFncponc0347_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/10732748040110S603","volume":"11","author":"R Stone","year":"2004","unstructured":"Stone R (2004) Treatment options for myelodysplastic syndromes. Cancer Control 11 (Suppl 6): 7\u201310","journal-title":"Cancer Control"},{"issue":"Suppl 6","key":"BFncponc0347_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/10732748040110S605","volume":"11","author":"A List","year":"2004","unstructured":"List A (2004) Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes. Cancer Control 11 (Suppl 6): 16\u201319","journal-title":"Cancer Control"},{"key":"BFncponc0347_CR9","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG and Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042\u20132054","journal-title":"N Engl J Med"},{"key":"BFncponc0347_CR10","unstructured":"Anon (online 1 September 05) Press release: approvable letter received from the FDA for Dacogen\u2122. [http:\/\/investors.mgipharma.com\/phoenix.zhtml?c=73842&p=irol-newsArticle&ID=751908&highlight=] (accessed 12 September 2005)"},{"key":"BFncponc0347_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","volume":"10","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E et al. (2005) FDA drug approval summary: azacidine (azacitidine\u2122) for injectable suspension. Oncologist 10: 176\u2013182","journal-title":"Oncologist"},{"key":"BFncponc0347_CR12","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","volume":"11","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E et al. (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11: 3604\u20133608","journal-title":"Clin Cancer Res"},{"key":"BFncponc0347_CR13","unstructured":"Anon (online 19 May 05) Vidaza label and approval history [http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Search_Drug_Name] (accessed 28 September 05)"},{"key":"BFncponc0347_CR14","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429\u20132440","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"BFncponc0347_CR15","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/S0145-2126(05)80172-9","volume":"29","author":"B R\u00fcter","year":"2005","unstructured":"R\u00fcter B et al. (2005) Re-treatment results in second remission of MDS with previous response to low-dose 5-aza-2\u2032-doxycytidine (Decitabine). Leuk Res 29 (Suppl): S65","journal-title":"Leuk Res"},{"key":"BFncponc0347_CR16","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.1200\/jco.2005.23.16_suppl.6545","volume":"23","author":"S O' Brien","year":"2005","unstructured":"O' Brien S et al. (2005) Decitabine low-dose schedule (100 mg\/m2\/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules [abstract]. J Clin Oncol 23: 6545","journal-title":"J Clin Oncol"},{"key":"BFncponc0347_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","volume":"18","author":"P Wijermans","year":"2000","unstructured":"Wijermans P et al. (2000) Low-dose 5-aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18: 956\u2013962","journal-title":"J Clin Oncol"},{"key":"BFncponc0347_CR18","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1200\/jco.2005.23.16_suppl.6544","volume":"23","author":"G Garcia-Manero","year":"2005","unstructured":"Garcia-Manero G et al. (2005) Results of a phase I\/II study of the combination of 5-aza-2\u2032-deoxycitidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome [abstract]. J Clin Oncol 23: 6544.","journal-title":"J Clin Oncol"},{"key":"BFncponc0347_CR19","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1200\/jco.2005.23.16_suppl.6543","volume":"23","author":"HI Saba","year":"2005","unstructured":"Saba HI et al. (2005) Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs. supportive care (SC) in patients with advanced myelodysplastic syndromes (MDS) [abstract]. J Clin Oncol 23: 6543","journal-title":"J Clin Oncol"},{"key":"BFncponc0347_CR20","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/1097-0142(197212)30:6<1639::AID-CNCR2820300633>3.0.CO;2-4","volume":"30","author":"SK Burchenal JH and Carter","year":"1972","unstructured":"Burchenal JH and Carter SK (1972) New cancer chemotherapeutic agents. Cancer 30: 1639\u20131646","journal-title":"Cancer"},{"key":"BFncponc0347_CR21","first-page":"2568","volume":"66","author":"A Massimo L and Comelli","year":"1975","unstructured":"Massimo L and Comelli A (1975) New drugs for the therapy of acute leukemia. Minerva Med 66: 2568\u20132576","journal-title":"Minerva Med"},{"issue":"Suppl 1","key":"BFncponc0347_CR22","first-page":"21","volume":"7","author":"LR Silverman","year":"1993","unstructured":"Silverman LR et al. (1993) Effects of treatment with azacitidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 (Suppl 1): 21\u201329","journal-title":"Leukemia"},{"issue":"Suppl 5","key":"BFncponc0347_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1634\/theoncologist.6-suppl_5-8","volume":"6","author":"LR Silverman","year":"2001","unstructured":"Silverman LR (2001) Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 6 (Suppl 5): 8\u201314","journal-title":"Oncologist"},{"key":"BFncponc0347_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0091270004271947","volume":"45","author":"G Marcucci","year":"2005","unstructured":"Marcucci G et al. (2005) Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 45: 597\u2013603","journal-title":"J Clin Pharmacol"},{"key":"BFncponc0347_CR25","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","volume":"20","author":"AB Kornblith","year":"2002","unstructured":"Kornblith AB et al. (2002) Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20: 2441\u20132452","journal-title":"J Clin Oncol"},{"key":"BFncponc0347_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1182\/blood.V104.11.1429.1429","volume":"104","author":"V Najfeld","year":"2004","unstructured":"Najfeld V et al. (2004) The modulating effect of azacitidine (Aza C) on the cytogenetically tracked MDS clone impact survival [abstract]. Blood 104: 1429","journal-title":"Blood"},{"issue":"Suppl 1","key":"BFncponc0347_CR27","first-page":"S35","volume":"11","author":"HM Kantarjian","year":"1997","unstructured":"Kantarjian HM et al. (1997) Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 11 (Suppl 1): S35\u2013S36","journal-title":"Leukemia"},{"key":"BFncponc0347_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/cncr.11543","volume":"98","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM et al. (2003) Results of decitabine (5-aza-2\u2032deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98: 522\u2013528","journal-title":"Cancer"},{"issue":"Suppl 1","key":"BFncponc0347_CR29","first-page":"51","volume":"7","author":"V Pinto A and Zagonel","year":"1993","unstructured":"Pinto A and Zagonel V (1993) 5-Aza-2\u2032-deoxycytidine (decitabine) and azacitidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 7 (Suppl 1): 51\u201360","journal-title":"Leukemia"},{"key":"BFncponc0347_CR30","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","volume":"103","author":"JP Issa","year":"2004","unstructured":"Issa JP et al. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635\u20131640","journal-title":"Blood"},{"key":"BFncponc0347_CR31","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/1097-0142(197811)42:5<2111::AID-CNCR2820420505>3.0.CO;2-I","volume":"42","author":"JH Saiki","year":"1978","unstructured":"Saiki JH et al. (1978) 5-Azacitidine in acute leukemia. Cancer 42: 2111\u20132114","journal-title":"Cancer"},{"key":"BFncponc0347_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","volume":"20","author":"SM Jones PA and Taylor","year":"1980","unstructured":"Jones PA and Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85\u201393","journal-title":"Cell"},{"key":"BFncponc0347_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/00001622-200311000-00007","volume":"15","author":"JP Issa","year":"2003","unstructured":"Issa JP (2003) Decitabine. Curr Opin Oncol 15: 446\u2013451","journal-title":"Curr Opin Oncol"},{"key":"BFncponc0347_CR34","first-page":"627","volume":"3","author":"JS Aparicio A and Weber","year":"2002","unstructured":"Aparicio A and Weber JS (2002) Review of the clinical experience with 5-azacytidine and 5-aza-2\u2032-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3: 627\u2013633","journal-title":"Curr Opin Investig Drugs"},{"key":"BFncponc0347_CR35","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/annonc\/mdf314","volume":"13","author":"E Goffin J and Eisenhauer","year":"2002","unstructured":"Goffin J and Eisenhauer E (2002) DNA methyltransferase inhibitors \u2014 state of the art. Ann Oncol 13: 1699\u20131716","journal-title":"Ann Oncol"},{"key":"BFncponc0347_CR36","unstructured":"National Comprehensive Cancer Network (online 21 September 04) Myelodysplastic syndromes Version 1.2005 [http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/mds.pdf] (accessed 7 September 2005)"},{"key":"BFncponc0347_CR37","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD et al. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96: 3671\u20133674","journal-title":"Blood"},{"key":"BFncponc0347_CR38","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","volume":"104","author":"CS Cutler","year":"2004","unstructured":"Cutler CS et al. (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104: 579\u2013585","journal-title":"Blood"},{"key":"BFncponc0347_CR39","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2141.1994.tb06733.x","volume":"87","author":"PJ Williamson","year":"1994","unstructured":"Williamson PJ et al. (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87: 743\u2013745","journal-title":"Br J Haematol"},{"key":"BFncponc0347_CR40","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1182\/blood-2003-12-4207","volume":"104","author":"AY Ho","year":"2004","unstructured":"Ho AY et al. (2004) Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104: 1616\u20131623","journal-title":"Blood"},{"key":"BFncponc0347_CR41","unstructured":"US Census Bureau (online 18 March 04) U.S. interim projections by age, sex, race, and Hispanic origin [http:\/\/www.census.gov\/ipc\/www\/usinterimproj\/natprojtab02a.pdf] and [http:\/\/www.census.gov\/ipc\/www\/usinterimproj\/natprojtab02b.pdf] (accessed 7 September 2005)"},{"key":"BFncponc0347_CR42","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","volume":"21","author":"JK Christman","year":"2002","unstructured":"Christman JK (2002) azacitidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21: 5483\u20135495","journal-title":"Oncogene"},{"key":"BFncponc0347_CR43","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1182\/blood.V97.9.2823","volume":"97","author":"M Toyota","year":"2001","unstructured":"Toyota M et al. (2001) Methylation profiling in acute myeloid leukemia. Blood 97: 2823\u20132829","journal-title":"Blood"},{"key":"BFncponc0347_CR44","first-page":"2217","volume":"8","author":"G Garcia-Manero","year":"2002","unstructured":"Garcia-Manero G et al. (2002) DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8: 2217\u20132224","journal-title":"Clin Cancer Res"},{"key":"BFncponc0347_CR45","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1200\/JCO.2005.07.450","volume":"23","author":"MA Rudek","year":"2005","unstructured":"Rudek MA et al. (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23: 3906\u20133911","journal-title":"J Clin Oncol"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncponc0347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncponc0347","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncponc0347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T17:33:44Z","timestamp":1650389624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":45,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2005,12,1]]}},"alternative-id":["BFncponc0347"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0347","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,1]]}}}